-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Researchers in children recently investigated the effect of replacing consolidation chemotherapy with Blinatumomab on the event-free survival rate of children with high-risk first recurrence of B-ALL before allogeneic hematopoietic stem cell transplantation.
Recently, researchers have investigated the effect of replacing consolidation chemotherapy with Blinatumomab on the event-free survival rate of children with high-risk first recurrence of B-ALL before allogeneic hematopoietic stem cell transplantation.
The event rates of the stem cell Blinatumomab group and the consolidation chemotherapy group were 31% and 57%, respectively (hazard ratio [HR]: 0.
33) The event rates of the Blinatumomab group and consolidation chemotherapy group were 31% and 57%, respectively (hazard ratio [HR] : 0.
33) For high-risk children with B-cell acute lymphoblastic leukemia who relapse for the first time, replacing the consolidation chemotherapy with Blinatumomab before allogeneic hematopoietic stem cell transplantation can significantly improve the event-free survival rate of the children.
For high-risk children with B-cell acute lymphoblastic leukemia who relapse for the first time, replacing the consolidation chemotherapy with Blinatumomab before allogeneic hematopoietic stem cell transplantation can significantly improve the event-free survival rate of the children.
Original source com/journals/jama/article-abstract/2776881" target="_blank" rel="noopener">Effect of Chemotherapy Blinatumomab VS-ON the Event as Free Survival Among Children With High-Risk-First Relapse the Cell Acute lymphoblastic Leukemia B-A Randomized Clinical Trial.
JAMA in this message
Recently, researchers have investigated the effect of replacing consolidation chemotherapy with Blinatumomab on the event-free survival rate of children with high-risk first recurrence of B-ALL before allogeneic hematopoietic stem cell transplantation.
The event rates of the stem cell Blinatumomab group and the consolidation chemotherapy group were 31% and 57%, respectively (hazard ratio [HR]: 0.
33) The event rates of the Blinatumomab group and consolidation chemotherapy group were 31% and 57%, respectively (hazard ratio [HR] : 0.
33) For high-risk children with B-cell acute lymphoblastic leukemia who relapse for the first time, replacing the consolidation chemotherapy with Blinatumomab before allogeneic hematopoietic stem cell transplantation can significantly improve the event-free survival rate of the children.
For high-risk children with B-cell acute lymphoblastic leukemia who relapse for the first time, replacing the consolidation chemotherapy with Blinatumomab before allogeneic hematopoietic stem cell transplantation can significantly improve the event-free survival rate of the children.
Original source com/journals/jama/article-abstract/2776881" target="_blank" rel="noopener">Effect of Chemotherapy Blinatumomab VS-ON the Event as Free Survival Among Children With High-Risk-First Relapse the Cell Acute lymphoblastic Leukemia B-A Randomized Clinical Trial.
JAMA in this message
